Richard Kootman
Ophthalmology · Peoria, AZNPI 1700896149
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,522 of the $5,756 with a category attached, or 78.6%. 21 manufacturers reported payments, led by Biotissue Holdings Inc. at 25.0% of the total. Reporting peaked in 2019 at $2,611 and has fallen 76.6% since, to $610 in 2025.
Across 63 payments — averaging $91.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biotissue Holdings Inc.$1K
- Sun Pharmaceutical Industries Inc.$626
- Rxsight Inc$472
- Alcon$416
- Bausch & Lomb, A Division Of Bausch Health US, LLC$407
- Kala Pharmaceuticals, Inc.$342
- plus $2K from 15 others
Across 8 payments — averaging $4250.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$34K
What the payments were for
- Speaking & faculty fees$260%
- Travel & lodging$1,20821%
- Food & beverage$4,52279%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biotissue Holdings Inc. | 9 | $1,441 |
| Sun Pharmaceutical Industries Inc. | 7 | $626 |
| Rxsight Inc | 6 | $472 |
| Alcon | 5 | $416 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 5 | $407 |
| Kala Pharmaceuticals, Inc. | 3 | $342 |
| Bausch & Lomb Americas Inc. | 4 | $335 |
| Dompe US, Inc. | 6 | $312 |
| AbbVie(2 entities) | 3 | $228 |
| Oyster Point Pharma, Inc. | 2 | $195 |
| Carl Zeiss Meditec USA, Inc. | 1 | $182 |
| Novartis | 2 | $140 |
| Glaukos Corporation | 2 | $138 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $127 |
| Shire North American Group Inc | 1 | $122 |
| Aerie Pharmaceuticals, Inc. | 1 | $102 |
| Genentech USA, Inc. | 1 | $81 |
| Tarsus Pharmaceuticals, Inc. | 1 | $27 |
| Novo Nordisk | 1 | $23 |
| Amgen | 1 | $23 |
| Medtronic | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Prokera$1,309
- AmnioGraft$1,309
- AmnioGuard$1,309
- CEQUA$500
- RXSIGHT CONTACT LENS$421
- RXSIGHT INJECTOR CARTRIDGE$421
- RXSIGHT INJECTOR HANDPIECE$421
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$421
- Tecnis IOL$382
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$261
- XIIDRA$247
- INVELTYS$237
- MIEBO$225
- VYZULTA$200
- LIGHT ADJUSTABLE LENS (LAL)$160
- iDoseTR$132
- Tecnis Simplicity$127
- VERITAS Vision System$127
- Clareon$123
- BROMSITE$119
How this compares
$5,756 in reported general payments places this provider in the 80th percentile of 310 ophthalmology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 84 | $43,599 |
| RestasisCyclosporine | 27 | $36,732 |
| XiidraLifitegrast | 28 | $29,124 |
| VyzultaLatanoprostene Bunod | 18 | $12,527 |
| Prednisolone Acetate | 179 | $9,442 |
| CombiganBrimonidine Tartrate/Timolol | 24 | $5,893 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 33 | $5,233 |
| MoxifloxacinMoxifloxacin Hcl | 74 | $1,890 |
| Latanoprost | 176 | $1,605 |
| Ofloxacin | 99 | $1,308 |
| Timolol Maleate | 50 | $552 |
| Doxycycline Hyclate | 14 | $368 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 23 | $325 |
| Dorzolamide Hcl | 11 | $316 |
| Acyclovir | 24 | $239 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $228 | $86,223135 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $335 | $41,65146 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 310 ophthalmology providers in Arizona.
Other ophthalmology in Peoria
- Lisa MihoraPeoria$91K
- Parminderpal SinghPeoria$9K
- Rahul IyengarPeoria$5K
- Warren HillMesa$1.1M
- Mark BarakatScottsdale$794K
- Anne ZakiSun City West$518K
- Pravin DugelPhoenix$176K
- Derek KunimotoMesa$138K
- Shamil PatelGlendale$116K
- Yuri McKeeMesa$100K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.